Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $181.84, for a total value of $13,638.00. Following the transaction, the executive vice president directly owned 21,308 shares in the company, valued at approximately $3,874,646.72. The trade was a 0.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Michael Feld also recently made the following trade(s):

• On Monday, January 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $202.73, for a total value of $15,204.75.
• On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.08, for a total value of $14,509.92.
• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $193.36, for a total transaction of $14,502.00.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded down $0.62 during trading hours on Friday, reaching $176.04. 4,298,153 shares of the company’s stock were exchanged, compared to its average volume of 2,956,077. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $50.12 billion, a price-to-earnings ratio of 28.72, a P/E/G ratio of 13.12 and a beta of 0.25. The company has a 50-day moving average of $196.07 and a 200 day moving average of $192.20.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the prior year, the company earned $3.43 earnings per share. The business’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has initiated a share buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Analyst Ratings Changes

A number of research firms recently weighed in on BDX. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Wells Fargo & Company lowered their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. TD Cowen increased their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. lowered their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Finally, Bank of America boosted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $195.46.

Institutional Trading of Becton, Dickinson and Company

Large investors have recently modified their holdings of the business. SOA Wealth Advisors LLC. raised its position in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Activest Wealth Management increased its position in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter worth $25,000. Steph & Co. lifted its position in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 65 shares in the last quarter. Finally, Bell Investment Advisors Inc boosted its stake in shares of Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 128 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.